Web9 Additional Meeting Information Other meetings which may take place during the life-cycle of an IND include: End of Phase 1 meetings (21 CFR 312.82) End of Phase 2/Pre-phase 3 meetings (21 CFR 312.47) Pre-BLA (Biologics Licensing Application) meetings (21 CFR 312.47) For more information, please see “Guidance for Industry: Formal Meetings with … WebINITIAL INVESTIGATIONAL NEW DRUG APPLICATION IND Title (if title being used) Serial 000 (Note to User: This template is intended for ‘simple’ INDs where commercially …
IND Application Template – ICTR – UW–Madison
WebMar 31, 2024 · Forms: Form FDA 1571 (PDF - 221KB ): Investigational New Drug Application (IND) Form FDA 1572 (PDF - 208KB): Statement of Investigator Form FDA 3674 (PDF - … department of health and human services. food and drug administration. disclosu… U.S. Food and Drug Administration WebPhysician Request for a Single Patient IND for Compassionate or Emergency Use When a physician would like to request an Investigational New Drug (IND) application to use an … campaign style office furniture
IND Application Procedures: Overview FDA
WebJul 12, 2024 · NIH applicants can use a template with instructional and sample text to help write clinical protocols for the following types of research: Phase 2 or 3 clinical trials that … Web1.2 Cover Letter - Initial IND Application 1.2 Cover Letter - Original NDA Application 1.2 Reviewer Guide 1.20 General Investigational Plan for Initial IND-2 1.20 General Investigational Plan for Initial IND 1.3.1.1 Change of Address 1.3.1.2 Change of Contact Agent 1.3.1.3 Change of Sponsor 1.3.1.4 Transfer of Obligation WebJun 9, 2024 · June 9, 2024 Regulatory guidelines allow for formal meetings between the FDA and sponsors or applicants to discuss the development and review of an investigational new drug (IND) application for drugs or biologic products. campaign thank you message